stockrow
Friday 6 November 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.
- Revenue
- +3.71%
- EPS
- +10.2%
- Free cash flow
- −24.9%
Quarter to September 2026, against a year earlier
124.40
19.26
−13.41%
Follow GRAL
Alert me
GRAIL, Inc. (GRAL) Revenue growth
GRAIL, Inc.'s revenue growth over the twelve months to 30 September 2026 was 17.5%, up 0.3 percentage points from fiscal 2025 (17.2%). That is above the Diagnostics & Research industry median of 8.99% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 17.2% | (17.72) |
| FY2024 | 34.9% | (32.71) |
| FY2023 | 67.6% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 3.71% | (22.01) |
| Jun 2026 | 25.7% | (2.39) |
| Mar 2026 | 28.1% | 14.14 |
| Dec 2025 | 14.0% | (12.35) |
| 5 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BLLN BillionToOne, Inc. compare | 76.5% |
| CDNA CareDx, Inc. compare | 38.9% |
| RDNT RadNet, Inc. compare | 18.9% |
| ADPT Adaptive Biotechnologies Corporation compare | 17.9% |
| VCYT Veracyte, Inc. compare | 17.5% |
| GRAL GRAIL, Inc. | 17.5% |
| SHC Sotera Health Company compare | 6.90% |
| QGEN QIAGEN N.V. compare | 2.96% |
| ICLR ICON PLC compare | 1.82% |
| Diagnostics & Research industry median | 8.99% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on GRAL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- The full statement